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Ataxia telangiectasia is acomplex multi-
systemic disorder with immunologic, 
neurologic, endocrinologic, hepatic and 
cutaneous abnormalities.It is 
characterized by progressive 
neurologicimpairment, cerebellar 
ataxia, variable immunodeficiency with 
increased susceptibility to sino-
pulmonary infections,impaired organ 
maturation, x-ray hypersensitivity, 
ocularand cutaneous telangiectasia, and 
a predisposition to malignancy 
AIM 
7b present a case of ataxia telangiectasia 
in an Byear old female. 
CASE REPORT 
An Byear old female with 5years history of 
recurrent cough and fast breathing, 
8years history of poor weight gain. She 
achieved normal early developmental 
milestones. She is the second child of 
adoptive parents and was adopted at 
2weeks of age. Her biological mother was 
said to have died immediately after 
delivery. Her adoptive parents were of 
high socioeconomic class. The detail of 
child's family history was not known to 
the adoptive parents. An initial diagnosis 
of upper respiratory tract infection to rule 
out pulmonary tuberculosis was made. 
Subsequently diagnosis was changed to 
recurrent bronchopneumonia in a child 
with primary immunodeficiency 
secondary to ataxia telangiectasia 
following recurrent cough and 
fastbreathing, appearance of ocular 
telangiectasia, onset of ataxia and result 
of investigations 4 years after initial 
presentation. She received several 
antibiotics in the course of the illness and 
also received anti tuberculous drugs. She 
also had human immunoglobulin therapy 
and was immunised with pneumococcal 
and influenza vaccines with some clinical 
response but subsequently died. 
CONCLUSION 
Ataxia telangiectasia is a rare multi-
systemic disorder with high morbidity 
and mortality in children. Delay in 
diagnosis and pulmonary complications 
contribute to a higher morbidity and 
mortality. There needs to be greater 
awareness of this disorder and its 
complications because early management 
with monitoring of lung function may 
improve outcome. 
KEYWORDS 
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INTRODUCTION 
Ataxia telangiectasia (A-T) was first described 
by Syllaba and Herner in 19261but described 
as a specific disorder in 1941 by Louis-Bar in a 
9year old Belgian child with progressive 
cellebellar ataxia and oculocutaneous 
telangiectasia. 2 Border et al3 in 1958 described 
organ developmental abnormalities, 
neurologic manifestations and a third major 
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feature of the disease recurrent count of 26%, normal platelet count of 227 X 
sinopulmonary infection with the aid of 109/L, PCV of37% and raised ESR of 14mm/hr. 
autopsies. They also recognized the familial Chest X-ray showed mottled opacities in the 
incidence proposing an autosomal recessive hilar and upper zones of both lungs and right 
mode of inheritance for the disease. Thus the lung base. Cardiac silhouette was normal and 
term ataxia telangiectasia was introduced. the thoracic cage was intact. There was no 
A-Tis a rare autosomal recessive multi system 
disorder characterized by progressive 
cerebellar ataxia, oculocutaneous 
telangiectasia, recurrent sinopulmonary 
infection, variable humoral and cellular 
immunodeficiency, high incidence of mainly 
Blymphoid malignancy and hypersensitivity 
to ionizing radiation. 4 Data on the prevalence 
of A-T in Nigeria is limited. Few cases of A-T 
have been reported in Nigeria. 5 The prevalence 
is about 1:40,000-100,000 birthsYit occurs in 
all races and affects males and females 
equally.8 
We report this case of A-T in Port Harcourt to 
highlight its existence, create more awareness 
about the disease and its complications in our 
children. 
CASE REPORT 
An 8year old female who first presented at the 
department of Paediatrics University of Port 
Harcourt Teaching Hospital at 3.5years of age 
with a complaints of cough and catarrh of 
3weeks duration. Cough was non paroxysmal, 
non distressful and worse at night. There was 
no history of contact with any case of chronic 
cough. Catarrh was productive of cream 
coloured discharge and free flowing. 
Examination findings at presentation 
revealed no significant abnormality in the 
systems. A diagnosis of upper respiratory tract 
infection to exclude pulmonary tuberculosis 
was made. She was asked to do Mantoux test, 
full blood count witherythrocyte 
sedimentation rate (ESR), chest X-ray and 
was commenced on syrup co-amoxiclavon out-
patient basis. 
She was reviewed a week later and results 
retrieved showed a negative Mantoux test, full 
blood count showed leucocytosis of 13.9 X109/L 
with absolute neutrophilia of7 4%, lymphocyte 
remarkable improvement as cough and 
catarrh persisted. Systemic examination 
findings were not remarkable. A diagnosis of? 
A typical pneumonia was made and she was 
commenced on syrup erythromycin. She was 
however lost to follow up thereafter. 
She presented again 3.5years later at age 7 
years with a 4years history of recurrent 
productive cough and 3years history of poor 
weight gain. She was noted to have been 
treated with anti- tuberculosis drugs category 
(CAT)I in a private hospital in the past. The 
treatment was interrupted after about 
4months because of apparent poor response. 
Examination findings on this visit were that 
she was chronically ill and wasted (weight was 
16kg: 72% expected),she had bilateral 
conjunctival injection and bilateral coarse 
crepitations on chest examination. Chest X-
ray showed diffuse miliary opacities especially 
in the left lung field. Full blood count showed 
leucocytosis with WBC count of 16.1 X 109/L 
with neutrophilia (neutrophils -75%, 
lymphocytes- 23%)and elevated ESR of 
24mm/hr. Retroviral screening for HIV I &II 
was seronegative and culture for acid fast 
bacilli (AFB)was negative for three 
consecutive sputum samples. A diagnosis of 
pulmonary tuberculosis with probably 
superimposed bacterial bronchopneumonia 
was made. She was admitted and commenced 
on intravenous antibiotics and CAT II anti 
tuberculous drugs. She was subsequently 
discharged after 3weeks and was on regular 
follow up. 
Subsequent review showed some clinical 
improvement but repeat Chest X-ray still 
showed patchy consolidations. Few weeks 
after completion of the anti-TB drugs for 
8months, examination showed that she was 
dyspnoeic, tachypnoiec with respiratory rate 
of 37cyle per minute, had reduced breath 
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DNA-dependent protein kinase localized 
predominantly to the nucleus and involved 
inmitogenic signal transduction, meiotic 
recombination and cell cycle control9.Defects 
in this function will result in increased rate of 
apoptotic cell death, radiosensitivity, and the 
premature death of neuronal cells, especially 
cerebellar Purkinje and granular cells10.The 
clinical and immunological presentation of 
ataxia-telangiectasia may differ even within 
the same family, as described by Soresinaet 
111 a. 
Major clinical and pathological features in A-T 
are progressive neurologic impairment, 
cerebellar ataxia, variable immunodeficiency 
with susceptibility to sinopulmonary 
infections, impaired organ maturation, x-ray 
hypersensitivity, ocular and cutaneous 
telangiectasia and a predisposition to 
malignancy. 4Ataxia is usually the 1"t 
diagnostic hallmark having its onset in the 1"t 
year of life. The progression becomes 
increasingly apparent beyond the age of 5 and 
child requires a wheel chair by 10-12years of 
age. 9 Mother was not sure of the age at onset of 
ataxia in our patient but was however noted in 
our patient at about 7years of age. Onset of 
oculocutaneous telangiectasia is typically at 3-
6years, onset in our patient was at 7years.9 
Studies have shown variable 
immunodeficiency in A-T patients and about 
50% of patients have recurrent sinopulmonary 
infection.12'13Pulmonary infections in A-T are 
usually caused by viruses during the first two 
years of life, and by common bacterial 
pathogens in later childhood, such as 
Hemophilusinfluenzae, Streptococcus 
pneumoniae, Pseudomonas aeruginosa and 
Staphylococcus aureus. These common 
infections are often correlated to the severity 
of humoral defect. 140ur patient had 
immunodeficiency with low levels of 
immunoglobulins and recurrent 
sinopulmonary infections. Incidence of 
malignancy have been found to be 60-300 
times higher than in healthy persons, and 
common tumours have been found to be of the 
lympho-reticular type.150ur patient had no 
evidence of malignancy and evidence for X 
ray hypersensitivity could not be ascertained 
because genetic studies on exposure to X ray 
was not done. In a study carried out by Moinet 
al16 among Iranian patients tocharacterize the 
clinical and immunologic features of 104 
patients with A-T, progressive ataxia was 
reported in 100% of them, 83.8% had ocular 
telangiectasia and 70.2% had cutaneous 
telangiectasia. Eye movement disorder was 
seen in 80.6%, 75% had acute recurrent 
infections, 53.9% had pneumonia while 64.9% 
had recurrent upper respiratory 
infection,87.1% had choreoathetosis and 
speech dysarthria was seen in almost all the 
patients. These features were all seen in our 
patient except cutaneous telangiectasia which 
may be masked by our patient's dark skin. 
A-T can be classified according to its major 
clinical and pathological features into type I-
IV.17Type I is the classic syndrome with all 
manifestation, Type II lacks some of the 
typical findings but shows radiosensitivity, 
Type III has the classic clinical findings but is 
not radiosensitive andType IV shows only 
some clinical features and is not 
radiosensitive. We could not classify our 
patient because we could not ascertain if she 
had radiosensitivity. 
The diagnosis of A-T is usually clinical but can 
be problematic before appearance of ataxia 
and telangiectasia. A-T diagnostic criteria was 
formulated by Ataxia-Telangiectasia Clinical 
Center at the Johns Hopkins Medical 
Institutions, which is as follows: 18'19 
Diagnostic criteria 118: Ataxia or significant 
motor incoordination with raised alpha 
fetoprotein (AFP) (>2x) +3 of the following four 
characteristic clinical features: 
1. In coordination of head and eyes in 
lateral gaze deflection 
2. Ocular telangiectasia 
3. Gait ataxia associated with an 
inappropriately narrow-base 
4. Immunoglobulin deficiencies 
Patients with less than three of these 
characteristics were required to have the 
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diagnosis confirmed by the finding of being affected, 50% chance of being 
radiation-induced chromosomal breaks in asymptomatic carriers and 25% chance of 
lymphocytes. Siblings of known patients with being unaffected. Heterozygotes (carriers) 
AT who are older than 1 year of age and had have an increased risk of developing cancer 
ataxia only needed tohaveanelevatedAFP. hence carrier testing for at-risk relatives and 
Diagnostic criteria 2: 19 Presence of 
characteristic neurologic features (gaitataxia, 
oculomotor dysfunction, dysarthria, and a 
movement disorder) and at least one of the 
following: 
1. Oculo-cutaneous telangiectasia 
2. Elevated levels of alpha-fetoprotein in 
3. 
serum 
Spontaneous or X irradiation-induced 
chromosomal breakage 
Our patient fulfilled both of these two 
diagnostic criteria. The diagnosis in our 
patient was made by clinical and laboratory 
findings. Laboratory markers are important 
for both diagnosis and prognosis. Elevated 
levels of AFP and carcinoembryonic 
antigen( CEA) are the most useful readily 
available markers for confirmation of the 
diagnosis 20 • Chromosomal studies to 
demonstrate spontaneous chromosomal 
breakage or following irradiation is also useful 
but requires special techniques and is only 
available in special centers. Our patient had 
markedly elevated AFP however CEA was not 
done and chromosomal studies could not be 
done. The dysgammaglobulinemia of A-T 
includes an absent or low level of IgA 
(including secretory IgA), a normal or low level 
ofigG, an elevated or normal level ofigM, IgE 
may also be absent or low. Elevated IgM is 
evident in only 60% of patients and IgA 
deficiency is found in about 70% of patients 
with A-T.21 Our patient had low level of IgG, 
IgM and IgA. Decreased cellular immune 
responses and peripheral lymphopenia are 
supportive findings. 
There is no specific treatment for A-T. 
However, gene therapy could be possible in the 
future and therefore genetic counseling is very 
important.22 Since the disorder is inherited in 
an autosomal recessive manner the siblings of 
an affected individual has a 25% chance of 
prenatal testing for pregnancies at increased 
risk are possible if the disease causmg 
mutations in the family are known. 23 
Treatment is symptomatic and supportive. 
Management requires amultidisciplinary 
approach involving the Pulmonologist, 
Immunologist, Neurologist, Dietician, 
Physiotherapist and Geneticist. The use of 
broad spectrum antibiotics in patients with 
infections is very useful. The development of 
safe and effective intravenous preparations of 
immunoglobulin represents a major advance 
in the treatment of patients with A-T as 
regular injection of immunoglobulins to 
prevent infection improves outcome. 
Immunization of patients against common 
respiratory pathogens should be routine to 
reduce respiratory infections. Recurrent 
sinopulmonary infections often lead to 
progressive pulmonary fibrosis which was 
seen in our patient. Mortality from A-T is 
commonly due to pulmonary disease, 50% die 
in adolescence from overwhelming 
bronchopulmonary disease. 24 Therefore early 
diagnosis of A-T and its pulmonary 
complications may reduce morbidity and 
mortality in our children. 
CONCLUSION 
A-T has a wide clinical heterogeneity and is 
often difficult to diagnose in children. It should 
be stressed that the course of the disease is 
variable and difficult to predict. Delay in 
diagnosis of A-T and its pulmonary 
complications contributes to morbidity and 
early mortality. There should be a high index 
of suspicion for A-T among children with 
recurrent infections and immunodeficiency to 
improve outcome. 
RECOMMENDATION 
Management of patients with A-T should be 
individualized according to specific needs as 
these patients need special attention to 
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improve their quality of life. The 
immunoglobulins should be made readily 
available and affordable to improve outcome. 
There should be more awareness about A-T 
and its pulmonary complications among 
Paediatricians to aid early diagnosis and 
prompt treatment in order to reduce early 
mortality due to lung disease. Carrier testing 
for at-risk relatives and prenatal testing for 
pregnancies at increased risk where facilities 
are available would be helpful. 
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